Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131


Targeting androgen receptor in estrogen receptor-negative breast cancer.

Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M.

Cancer Cell. 2011 Jul 12;20(1):119-31. doi: 10.1016/j.ccr.2011.05.026.


Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.

Breast Cancer Res. 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599.


FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.

Jones D, Wade M, Nakjang S, Chaytor L, Grey J, Robson CN, Gaughan L.

Oncotarget. 2015 Oct 6;6(30):29782-94. doi: 10.18632/oncotarget.4927.


The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH.

Breast Cancer Res. 2012 Feb 9;14(1):R27.


Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.


Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.

Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS, Dalton JT.

PLoS One. 2014 Jul 29;9(7):e103202. doi: 10.1371/journal.pone.0103202. eCollection 2014.


Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer.

Zhu A, Li Y, Song W, Xu Y, Yang F, Zhang W, Yin Y, Guan X.

Cell Physiol Biochem. 2016;38(3):1003-14. doi: 10.1159/000443052. Epub 2016 Mar 4.


Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.

Ray S, Johnston R, Campbell DC, Nugent S, McDade SS, Waugh D, Panov KI.

Gene. 2013 Aug 15;526(1):46-53. doi: 10.1016/j.gene.2013.04.018. Epub 2013 Apr 19.


Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.

Zhao L, Niu F, Shen H, Liu X, Chen L, Niu Y.

Virchows Arch. 2016 Jun;468(6):687-96. doi: 10.1007/s00428-016-1930-0. Epub 2016 Mar 30.


Targeting androgen receptor/Src complex impairs the aggressive phenotype of human fibrosarcoma cells.

Castoria G, Giovannelli P, Di Donato M, Hayashi R, Arra C, Appella E, Auricchio F, Migliaccio A.

PLoS One. 2013 Oct 9;8(10):e76899. doi: 10.1371/journal.pone.0076899. eCollection 2013.


Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.

Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW, Lee KS.

Ann Oncol. 2011 Aug;22(8):1755-62. doi: 10.1093/annonc/mdq678. Epub 2011 Feb 10.


Lin28A and androgen receptor expression in ER-/Her2+ breast cancer.

Shen H, Yang Y, Zhao L, Yuan J, Niu Y.

Breast Cancer Res Treat. 2016 Feb;156(1):135-47. doi: 10.1007/s10549-016-3744-9. Epub 2016 Mar 5.


Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011).

Clin Cancer Res. 2013 Oct 1;19(19):5505-12. doi: 10.1158/1078-0432.CCR-12-3327. Epub 2013 Aug 21.


[Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status].

Chen J, Zhang X, Tian R, Liu Y, Dong HM, Guo RF, Liang HY.

Zhonghua Bing Li Xue Za Zhi. 2010 Nov;39(11):743-6. Chinese.


Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.

Segal CV, Koufaris C, Powell C, Gooderham NJ.

Toxicology. 2015 Jul 3;333:45-52. doi: 10.1016/j.tox.2015.04.002. Epub 2015 Apr 3.


Supplemental Content

Support Center